TAIPEI, Taiwan – The global biotech market is in a period of low productivity, high costs and less-than-ideal levels of efficiency. Such conditions are pushing pharmaceutical firms in the Asia-Pacific region to develop creative strategies that often require looking elsewhere for innovative solutions and products.
TAIPEI, Taiwan – During the two days of talks, roundtables and panel discussions at Biologics World Taiwan 2017, much of the attention speakers devoted to Taiwan focused on what the country is not getting right, from government support and policies, to competing with regional rivals.
TAIPEI, Taiwan – The government here, despite its good intentions, needs to make changes in its approach to the biopharma industry quickly, said speakers on the first day of the Biologics World Taiwan 2017 conference.
HONG KONG – With five drugs in its pipeline and a deal with big pharma worth tens of millions of dollars, Singapore drug developer Aslan Pharmaceuticals Pte Ltd. aims to tap the markets in Taiwan, looking to overcome some flagging investor sentiment on biopharma.
TAIPEI, Taiwan – Calling its recent FDA orphan designation for small-molecule drug CX-4945 in cholangiocarcinoma an important milestone in its development and regulatory strategy, 2012 startup Senhwa Biosciences Inc. enters 2017 with plans for an uplisting on the Taiwan stock exchange and hopes for restoring investor enthusiasm for Taiwan's biopharma sector.
HONG KONG – With five drugs in its pipeline and a deal with big pharma worth tens of millions of dollars, Singapore drug developer Aslan Pharmaceuticals Pte Ltd. aims to tap the markets in Taiwan, looking to overcome some flagging investor sentiment on biopharma.
TAIPEI, Taiwan – Calling its recent FDA orphan designation for small-molecule drug CX-4945 in cholangiocarcinoma an important milestone in its development and regulatory strategy, 2012 startup Senhwa Biosciences Inc. enters 2017 with plans for an uplisting on the Taiwan stock exchange and hopes for restoring investor enthusiasm for Taiwan's biopharma sector.
